PET DEMONSTRATES DIFFERENT BEHAVIOR OF STRIATAL DOPAMINE D-1 AND D-2 RECEPTORS IN EARLY PARKINSONS-DISEASE

被引:77
作者
RINNE, JO
LAIHINEN, A
NAGREN, K
BERGMAN, J
SOLIN, O
HAAPARANTA, M
RUOTSALAINEN, U
RINNE, UK
机构
[1] UNIV TURKU,TURKU MED CYCLOTRON LAB,SF-20520 TURKU 52,FINLAND
[2] UNIV TURKU,CENT HOSP,PET CTR,SF-20520 TURKU 52,FINLAND
[3] SWEDISH UNIV TURKU,ACCELERATOR LAB,SF-20500 TURKU 50,FINLAND
关键词
DOPAMINE; D-1; RECEPTORS; D-2; PARKINSONS DISEASE; POSITRON EMISSION TOMOGRAPHY; RACLOPRIDE; SCH; 23390;
D O I
10.1002/jnr.490270409
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Striatal dopamine D-1 receptor binding was investigated in vivo with positron emission tomography (PET) in five patients with early Parkinson's disease using [C-11]-SCH 23390. All patients had predominantly unilateral symptoms and showed a significant reduction in the accumulation of [F-18]-6-F-DOPA in the striatum contralateral to the symptoms. None of the patients had received any antiparkinsonian medication. The striatal and cerebellar radioactivity was measured and corresponding striatum/cerebellum ratios were counted. The mean striatum/cerebellum ratio of [C-11]-SCH 23390 binding was symmetric between the hemispheres. By contrast, the striatum/cerebellum ratio of [C-11]raclopride binding, labelling dopamine D-2 receptors, was increased significantly in the hemisphere contralateral to the symptoms as compared with the opposite hemisphere. Thus, the present results show that the behaviour of striatal D-1 and D-2 receptors is different in early Parkinson's disease.
引用
收藏
页码:494 / 499
页数:6
相关论文
共 31 条
[1]  
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
[2]   CHARACTERIZATION OF THE BINDING OF H-3-SCH 23390, A SELECTIVE D-1 RECEPTOR ANTAGONIST LIGAND, IN RAT STRIATUM [J].
BILLARD, W ;
RUPERTO, V ;
CROSBY, G ;
IORIO, LC ;
BARNETT, A .
LIFE SCIENCES, 1984, 35 (18) :1885-1893
[3]   THE D-1 DOPAMINE RECEPTOR ANTAGONIST SCH 23390 ALSO INTERACTS POTENTLY WITH BRAIN-SEROTONIN (5-HT2) RECEPTORS [J].
BISCHOFF, S ;
HEINRICH, M ;
SONNTAG, JM ;
KRAUSS, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 129 (03) :367-370
[4]   STIMULATION OF BOTH D1 AND D2 DOPAMINE-RECEPTORS APPEARS NECESSARY FOR FULL EXPRESSION OF POSTSYNAPTIC EFFECTS OF DOPAMINE AGONISTS - A NEUROPHYSIOLOGICAL STUDY [J].
CARLSON, JH ;
BERGSTROM, DA ;
WALTERS, JR .
BRAIN RESEARCH, 1987, 400 (02) :205-218
[5]  
DUVOISIN RC, 1971, MONOAMINES NOYAUX GR, P313
[6]   PET ANALYSIS OF HUMAN DOPAMINE RECEPTOR SUBTYPES USING C-11 SCH 23390 AND C-11 RACLOPRIDE [J].
FARDE, L ;
HALLDIN, C ;
STONEELANDER, S ;
SEDVALL, G .
PSYCHOPHARMACOLOGY, 1987, 92 (03) :278-284
[7]   CENTRAL DOPAMINERGIC PATHWAYS IN HEMIPARKINSONISM EXAMINED BY POSITRON EMISSION TOMOGRAPHY [J].
GARNETT, ES ;
NAHMIAS, C ;
FIRNAU, G .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1984, 11 (01) :174-179
[8]   HUMAN DOPAMINE RECEPTOR SUBTYPES - INVITRO BINDING ANALYSIS USING H-3 SCH 23390 AND H-3 RACLOPRIDE [J].
HALL, H ;
FARDE, L ;
SEDVALL, G .
JOURNAL OF NEURAL TRANSMISSION, 1988, 73 (01) :7-21
[9]  
HALLDIN C, 1986, INT J APPL RADIAT IS, V37, P1038
[10]   DOPAMINE-RECEPTORS IN PARKINSONS-DISEASE [J].
HASSAN, MN ;
THAKAR, JH .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1988, 12 (2-3) :173-182